Guggenheim Lowers Eli Lilly and Company (NYSE:LLY) Price Target to $1,163.00

Eli Lilly and Company (NYSE:LLY) had its target price cut by investment analysts at Guggenheim from $1,168.00 to $1,163.00 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s target price would suggest a potential upside of 30.24% from the company’s current price.

Several other research analysts also recently issued reports on LLY. Freedom Capital upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 10th. HSBC downgraded shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and decreased their price target for the stock from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. CICC Research increased their target price on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 11th. TD Cowen upped their price target on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Thursday, January 29th. Finally, Bank of America reduced their target price on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating on the stock in a research report on Monday, December 15th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $1,221.26.

Eli Lilly and Company Trading Up 1.7%

NYSE:LLY opened at $892.99 on Monday. The company has a market capitalization of $843.71 billion, a P/E ratio of 38.87, a P/E/G ratio of 1.02 and a beta of 0.40. The stock’s 50 day moving average price is $1,007.25 and its 200 day moving average price is $964.88. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same period last year, the company earned $5.32 earnings per share. The business’s revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Institutional Trading of Eli Lilly and Company

A number of institutional investors have recently bought and sold shares of LLY. 10Elms LLP lifted its holdings in Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 10 shares in the last quarter. M.E. Allison & CO. Inc. grew its stake in Eli Lilly and Company by 0.7% in the 4th quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company’s stock worth $1,587,000 after acquiring an additional 10 shares in the last quarter. Tanager Wealth Management LLP increased its position in shares of Eli Lilly and Company by 2.6% during the fourth quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock worth $424,000 after acquiring an additional 10 shares during the period. Wealthspan Partners LLC raised its stake in shares of Eli Lilly and Company by 0.5% during the fourth quarter. Wealthspan Partners LLC now owns 2,110 shares of the company’s stock valued at $2,268,000 after acquiring an additional 10 shares in the last quarter. Finally, Morey & Quinn Wealth Partners LLC raised its stake in shares of Eli Lilly and Company by 1.5% during the fourth quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company’s stock valued at $710,000 after acquiring an additional 10 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Big AI R&D pact — Lilly expanded its collaboration with Insilico Medicine in a deal worth up to $2.75 billion to accelerate AI-driven drug discovery; the agreement gives Lilly exclusive rights to programs and includes upfront and milestone payments, reinforcing growth optionality and R&D scale. Lilly further embraces Insilico’s AI tech, inking R&D collab worth up to $2.75B
• Positive Sentiment: Clinical readout boosts pipeline optionality — Late‑breaking Phase 3b TOGETHER‑PsA data showed Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy vs Taltz alone in psoriatic arthritis patients with obesity, supporting cross‑product synergies and potential label/market expansion. Phase 3b data presented at AAD Annual Meeting show Lilly’s Taltz plus Zepbound delivered superior efficacy
• Positive Sentiment: Analyst support — Jefferies reiterated a Buy on LLY with a $1,300 price target, citing strong GLP‑1 prescription data and continued franchise momentum, which can underpin investor confidence despite recent volatility. Jefferies Remains a Buy on Eli Lilly
• Neutral Sentiment: Macro/market mentions — Lilly is featured among broader market movers and media commentary (Jim Cramer, coverage pieces) that may amplify flows but are not new company‑specific catalysts. These Stocks Are Today’s Movers
• Negative Sentiment: UK pricing / investment threat — Reports say Lilly is seeking regular NHS price increases and changes to rebate rules as conditions to restart UK investment; this kind of public negotiation raises political and reimbursement risk that can pressure valuation and access in a major market. Eli Lilly seeks higher NHS drug prices, rebate overhaul to restart UK investment
• Negative Sentiment: Valuation and short‑term pullback concerns — Commentary and screeners flag an ongoing price pullback and questions about whether the stock is priced for perfection, which can trigger further profit‑taking after a multiyear run. Is It Time To Reassess Eli Lilly After The Recent Share Price Pullback?
• Negative Sentiment: Legal/operational distraction — Lilly has escalated a whistleblower-law fight to the U.S. Supreme Court; while not a direct revenue risk today, legal headlines can add regulatory/PR noise. Indy Pharma Giant Eli Lilly Takes Whistleblower Law Fight To Supreme Court

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.